• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Twelve new members join DF/HCC

Twelve individuals have recently joined DF/HCC. See below to learn more about these scientists and their research interes

Zoltan Arany, MD, PhD (BIDMC)
Angiogenesis, Invasion, and Metastasis

Research focus: The lab studies gene regulatory pathways underlying cardiovascular disease, with a specific interest in angiogenesis and blood vessel homeostasis. Efforts are underway to test if this pathway is active in angiogenesis associated with neoplastic progression, as well as other pathological processes, and to investigate the molecular mechanisms underlying this novel pathway.

David Breault, MD, PhD (CHB)
Gastrointestinal Malignancies

Research focus: The lab is focused on the idea that a slowly cycling stem cell population exists within the intestine and further indicates that multiple stem cell populations can co-exist within the same mammalian tissue. These results support the notion that independent or co-dependent stem cell populations may serve different functions during the life of an organism.


Gerald Chu, MD, PhD (DFCI)
Gastrointestinal Malignancies

Research focus: The lab focuses on PDAC microenvironment research with an emphasis on how inflammatory processes and key cancer pathways may shape the ontogeny of the tumor stroma. Genetically engineered mouse models, xenograft transplant models, and human tumor specimens are examined with a system-wide biological approach.

Vadim Gladyshev, PhD (BWH)
Cancer Genetics

Research focus: The laboratory is working to understand redox regulation of cellular processes. The focus is on thiol oxidoreductase functions and their targets and roles in disease. The lab develops and employs various high-throughput approaches  using genome sequencing, proteomics, bioinformatics, and functional genomics methods; this is followed with in vitro and in vivo studies.

Alfred Goldberg, PhD (HMS)
Cancer Cell Biology

Research focus: The lab studies the physiological regulation and molecular mechanisms of protein breakdown by the ubiquitin proteasome pathway in eukaryotic cells with the primary goal to understand how overall proteolysis in muscle is accelerated and causes muscle atrophy in various disease states (e.g. cancer cachexia).


Chung Yin Kong, PhD (MGH)
Outcomes Research

Research focus: The research of the laboratory translates the existing modeling methods to improve health policy simulation models and focuses primarily on the development and calibration of complex microsimulation models.

Erica Mayer, MD, MPH (DFCI)
Angiogenesis, Invasion, and Metastasis; Breast Cancer

Research focus: The lab investigates the use of the anti-angiogenic  regimen of Vandetanib and metronomic chemotherapy in advanced breast cancer. They seek to define the effects of this all-oral combination therapy with the primary endpoints being safety and toxicity and the secondary endpoints being response rate, non-invasive vascular analysis of hypertension, and platelet proteomics.

Sung-Yun Pai, MD (HMS)
Cancer Immunology

Research focus: Current work focuses on the molecular mechanisms underlying congenital immunodeficiency and immune reconstitution and complications after cellular therapies including insertional mutagenesis after gene transfer.

Giovanni Parmigiani, PhD (DFCI)

Research focus: The laboratory focuses on models and software to predict those at risk for genetic variants that confer susceptibility to cancer; statistical methods for the analysis of high throughput genomic data and for complex medical decisions; and Bayesian modeling and computation.

Carlos Rodriguez-Galindo, MD (DFCI)
Translational Pharmacology and Early Therapeutic Trials

Research focus: The laboratory concentrates on the development of innovative therapies for pediatric solid tumors, in particular retinoblastoma, sarcomas, and rare cancers. Additional research initiatives in pediatric malignancies include extensive work on the Ewing sarcoma, osteosarcoma, and soft tissue sarcomas.

Jacalyn Rosenblatt, MD, MMSc (BIDMC)
Cancer Immunology; Lymphoma and Myeloma

Research focus: The lab examines the nature of host immunity in the setting of malignancy and identifies approaches to circumvent tumor mediated immune suppression to augment vaccine response. In addition, the team is studying the ability of dendritic cell based tumor vaccines to target the leukemia stem cell population in AML.

Huiyan Zeng, PhD (BIDMC)
Angiogenesis, Invasion, and Metastasis

Research focus: The laboratory currently focuses on the molecular mechanism and signaling pathways that induce and regulate tumor angiogenesis including gene profile studies in order to find attractive targets for anti-angiogenesis therapy.